SCHEMBL4849633

SCHEMBL4849633

CCc1ccc(C(=O)c2ccncc2OCOCC[Si](C)(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CCNC P24863 4/20 0.37
CDK8 P49336 4/20 0.37
TRPV1 Q8NER1 1/20 0.36
LMNA P02545 2/20 0.35
TSHR P16473 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
CYP19A1 P11511 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2580701 0.84 KDM4C (0.38) MAPTKMT2ANPSR1CCNCCDK8
SCHEMBL4859922 0.76 IDO1 (0.33) KMT2ANPSR1CCNCCDK8LMNA
SCHEMBL4698645 0.72 CA12 (0.42) SMN1; SMN2MAPTKMT2ANPSR1LMNA
SCHEMBL4849875 0.71 SMN1; SMN2 (0.50) SMN1; SMN2MAPTHTTKMT2ANPSR1
SCHEMBL4701131 0.70 ALOX5AP (0.42) MAPT
SCHEMBL4705428 0.70 ALOX5AP (0.35) MAPT
SCHEMBL4857523 0.70 ALDH1A1 (0.36) SMN1; SMN2MAPTHTTKMT2ALMNA
SCHEMBL6385422 0.69 KDM4E (0.35) SMN1; SMN2MAPTHTTKMT2ACCNC
SCHEMBL4860187 0.69 SMN1; SMN2 (0.50) SMN1; SMN2MAPTHTTKMT2ANPSR1
SCHEMBL4907075 0.68 MAPT (0.47) SMN1; SMN2MAPTKMT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 SMN1; SMN2 4397/4885MAPT 1124/4885HTT 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.